Левофлоксацин (Таваник) в лечении внебольничной пневмонии у взрослых

1. Lesher GY, Froelich ED, Gruett MD et al. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5: 1063–8.
2. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003; 51 (Suppl. S1): 13–20.
3. Naber K, Adam D. Expertengruppe der PEG. Einteilung der Fluorchinolone. Chemother J 1998; 7: 66–8. 
4. Langtry HD, Lamb HM. Levofloxacin: Its use in infections of respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487–515.
5. National Committee for Clinical Laboratory Standars. Perfomance standards for antimicrobial susceptibility testing: twelfth informational supplement. V. 22 Wayne (PA); 2002. NCCLS document M100–S12.
6. Lynch JP, File TM, Zhanel GG. Levofloxacin for the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther 2006; 4: 725–42.
7. Felmingham D, Feldman C, Hryniewicz W et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8 (Suppl. 2): 12–42.
8. Liu HH. Safety Profile of the Fluoroquinolones. Focus one Levofloxacin. Drug Saf 2010; 33 (5): 353–69.
9. Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139–48.
10. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–2001. J Infect 2004; 48: 56–65.
11. Noreddin AM, WF Elkhatib. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther 2010; 8: 505–14.
12. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (4): 329–41.
13. File TM Jr, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 33: 1965–72.
14. Norrby SR, Petermann W, Willcox PA et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397–404.
15. Gotfried MH, Dattani D, Riffer E et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736–51.
16. Frank E, Liu J, Kinasewitz G et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24: 1292–308.
17. Fogarty C, Siami G, Kohler R et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38: S16–S23.
18. D’Ignazio J, Canere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia. Antimicrob Agents Chemother 2005; 49: 4035–41.
19. Dunbar LM, Wunderick RG, Habib MP et al. High-dose, short course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752–60.
20. Shorr AF, Zadeikis N, Xiang JX et al. A multicenter, randomized, double-blind retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients ≥65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251–9.
21. Erard V, Lamy O, Bochud PY et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2004; 23: 82–8.
22. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–83.
23. Anzueto A, Niederman MS, Pearl J et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxofloxacin therapy versus that levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81.
24. Akpunonu B, Michaelis J, Uy CN et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004; 38 (Suppl. 1): S5–S15.
25. Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. J Am Med Assos 2000; 283: 749–55.
26. Yu VL, Greenbery RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135–9.
27. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Francis L et al. Antibacterial chemotherapy for legionnaries disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800–6.
28. Mykietiuk A, Carratal J, Fernandez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794–9.
29. Kahn JB, Wiesinger A, Xiang J. Macrolide-resistance Streptococcus pneumoniae in community-acquired pneumonia: clinical and microbiological outcomes for patients treated with levofloxacin. Clin Infect Dis 2004; 38 (Suppl. 1): S24–S33.
30. Olive D, Georges H, Devos P et al. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis 2011; 11: 66–73.
31. Kuhn F, Cottagnoud M, Acosta F et al. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003, 47: 2487–91.
32. Gimeno C, Boria J, Navarro D et al. In vitro interaction between ofloxacin and cefotaxime against grampositive and gramnegative bacteria involved in serious infections. Chemotherapy 1998, 44: 94–8.
33. Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30: 358–70.
34. Hess G, Hill JW, Raut MK et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: results from a claims analysis. Adv Ther 2010; 27: 743–55.
35. Vardakas KZ, Siempos II, Grammatikos A et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Can Med Assoc J 2008; 179: 1269–77.
36. Ball P. Role of levofloxacin in the treatment of lower respiratory tract infections. Penetration: New challenges for levofloxacin in the fight against infectious diseases. Annual Issue 2003. Tokyo: BIOMEDIS 2003: 22–32.
37. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006; 22: 1997–2006.
38. Tillotson G, Ball P. Fluoroquinolone safety profiles – A review. Today’s Therapeutic Trends 2002; 20: 419–35.
39. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on new agents. Clin Infect Dis 1999; 28: 352–64.
40. Levaquin® (Levofloxacin tablets, oral solution, injection): US prescribing information. OrthoMcNeil Pharmaceutical, Inc., Raritan, Nj, USA, 2009.
41. Thiem U, Heppner HJ, Pientka L. Elderly patients with community-acquired pneumonia. Optimal treatment strategies. Drugs Aging 2011; 28: 519–37.

А.И.Синопальников 

ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ, Москва